Paratek Pharmaceuticals

Paratek Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative antibiotics to address significant unmet medical needs. Their primary product, NUZYRA®, is an FDA-approved tetracycline-class antibiotic aimed at treating community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria. The company is dedicated to tackling the global health crisis of antimicrobial resistance (AMR) through responsible antibiotic use, research, and policy advocacy. Paratek stands out as a leader in addressing these complex medical challenges with its experienced team of professionals committed to saving lives.